Last reviewed · How we verify
Suvorexant High Dose (HD)
Suvorexant High Dose (HD) is a Orexin receptor antagonist Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Insomnia (sleep onset and/or sleep maintenance). Also known as: MK-4305.
Suvorexant is an orexin receptor antagonist that blocks wake-promoting signals in the brain to promote sleep onset and maintenance.
Suvorexant is an orexin receptor antagonist that blocks wake-promoting signals in the brain to promote sleep onset and maintenance. Used for Insomnia (sleep onset and/or sleep maintenance).
At a glance
| Generic name | Suvorexant High Dose (HD) |
|---|---|
| Also known as | MK-4305 |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Orexin receptor antagonist |
| Target | OX1R and OX2R (orexin receptors 1 and 2) |
| Modality | Small molecule |
| Therapeutic area | Neurology / Sleep Medicine |
| Phase | Phase 3 |
Mechanism of action
Suvorexant selectively antagonizes orexin receptors OX1R and OX2R, which are neuropeptide receptors involved in maintaining wakefulness. By blocking these receptors, the drug reduces the activity of wake-promoting neurons, thereby facilitating sleep initiation and consolidation. The high-dose formulation is being evaluated to assess efficacy and safety at elevated exposure levels.
Approved indications
- Insomnia (sleep onset and/or sleep maintenance)
Common side effects
- Somnolence / next-day drowsiness
- Headache
- Dizziness
- Abnormal dreams / nightmares
- Sleep paralysis
Key clinical trials
- Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029) (PHASE3)
- Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Suvorexant High Dose (HD) CI brief — competitive landscape report
- Suvorexant High Dose (HD) updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Suvorexant High Dose (HD)
What is Suvorexant High Dose (HD)?
How does Suvorexant High Dose (HD) work?
What is Suvorexant High Dose (HD) used for?
Who makes Suvorexant High Dose (HD)?
Is Suvorexant High Dose (HD) also known as anything else?
What drug class is Suvorexant High Dose (HD) in?
What development phase is Suvorexant High Dose (HD) in?
What are the side effects of Suvorexant High Dose (HD)?
What does Suvorexant High Dose (HD) target?
Related
- Drug class: All Orexin receptor antagonist drugs
- Target: All drugs targeting OX1R and OX2R (orexin receptors 1 and 2)
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Neurology / Sleep Medicine
- Indication: Drugs for Insomnia (sleep onset and/or sleep maintenance)
- Also known as: MK-4305
- Compare: Suvorexant High Dose (HD) vs similar drugs
- Pricing: Suvorexant High Dose (HD) cost, discount & access